“`html
BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company, has announced a 1-for-10 share consolidation (reverse stock split) to maintain Nasdaq listing compliance. The consolidation is set to take effect on August 25, 2025.
Under the consolidation terms, shareholders will receive one new share for every ten existing shares. Fractional shares will be handled by rounding up fractions of ½ or greater to one whole share, while smaller fractions will be cancelled. The company’s convertible securities will be proportionally adjusted.
Post-consolidation, BriaCell will continue trading under the symbols BCT on TSX and BCTX on Nasdaq. Registered shareholders will receive transmittal letters from Computershare Investor Services with exchange instructions.
BriaCell Therapeutics (NASDAQ: BCTX), una società biotecnologica in fase clinica, ha annunciato una consolidazione azionaria 1-per-10 (split inverso) per mantenere la conformità ai requisiti di quotazione del Nasdaq. La consolidazione entrerà in vigore il 25 agosto 2025.
Secondo i termini, gli azionisti riceveranno una nuova azione ogni dieci azioni possedute. Le frazioni di azione saranno gestite arrotondando verso l’alto le frazioni pari o superiori a ½ a una azione intera; le frazioni inferiori saranno annullate. Anche gli strumenti convertibili della società saranno adeguati proporzionalmente.
Dopo la consolidazione, BriaCell continuerà a essere negoziata con i simboli BCT sulla TSX e BCTX sul Nasdaq. Gli azionisti registrati riceveranno lettere di trasmissione da Computershare Investor Services con le istruzioni per lo scambio.
BriaCell Therapeutics (NASDAQ: BCTX), una compañía biotecnológica en fase clínica, ha anunciado una consolidación de acciones 1 por 10 (reverse stock split) para mantener el cumplimiento de las normas de cotización en Nasdaq. La consolidación entrará en vigor el 25 de agosto de 2025.
Según los términos, los accionistas recibirán una acción nueva por cada diez acciones antiguas. Las fracciones de acción se gestionarán redondeando hacia arriba las fracciones de ½ o más hasta una acción completa; las fracciones menores se cancelarán. Los valores convertibles de la compañía se ajustarán proporcionalmente.
Tras la consolidación, BriaCell seguirá cotizando con los símbolos BCT en la TSX y BCTX en Nasdaq. Los accionistas registrados recibirán cartas de transmisión de Computershare Investor Services con instrucciones para el intercambio.
BriaCell Therapeutics (NASDAQ: BCTX)는 임상 단계의 생명공학 회사로서 나스닥 상장 규정 준수를 위해 1대10 액면병합(역주식분할)을 발표했습니다. 병합은 2025년 8월 25일에 발효됩니다.
병합 조건에 따라 주주들은 기존 10주당 신주 1주를 받게 됩니다. 주식의 소수점(분할)은 ½ 이상인 경우 1주로 반올림하여 처리하고, 그보다 작은 분수는 소멸됩니다. 회사의 전환증권 또한 비례하여 조정됩니다.
병합 후 BriaCell은 TSX에서는 BCT, Nasdaq에서는 BCTX로 계속 거래됩니다. 등록주주들은 교환 절차에 대한 안내문을 Computershare Investor Services로부터 받게 됩니다.
BriaCell Therapeutics (NASDAQ: BCTX), une société biotechnologique en phase clinique, a annoncé une consolidation d’actions 1 pour 10 (fractionnement inverse) afin de rester conforme aux exigences de cotation du Nasdaq. La consolidation prendra effet le 25 août 2025.
Conformément aux modalités, les actionnaires recevront une nouvelle action pour dix actions détenues. Les fractions d’actions seront traitées en arrondissant à l’unité les fractions de ½ ou plus ; les fractions inférieures seront annulées. Les titres convertibles de la société seront ajustés proportionnellement.
Après la consolidation, BriaCell continuera d’être négociée sous les symboles BCT sur la TSX et BCTX sur le Nasdaq. Les actionnaires inscrits recevront des lettres de transmission de Computershare Investor Services contenant les instructions d’échange.
BriaCell Therapeutics (NASDAQ: BCTX), ein Biotechnologieunternehmen in der klinischen Phase, hat eine Aktienzsmlegung im Verhältnis 1:10 (Reverse Stock Split) angekündigt, um die Anforderungen der Nasdaq-Notierung zu erfüllen. Die Zusammenlegung tritt am 25. August 2025 in Kraft.
Nach den Bedingungen erhalten Aktionäre eine neue Aktie für je zehn bestehende Aktien. Bruchstücke werden so behandelt, dass Bruchteile von ½ oder mehr auf eine ganze Aktie aufgerundet werden; kleinere Bruchteile entfallen. Die wandelbaren Wertpapiere des Unternehmens werden anteilig angepasst.
Nach der Konsolidierung wird BriaCell weiterhin unter den Symbolen BCT an der TSX und BCTX an der Nasdaq gehandelt. Eingetragene Aktionäre erhalten von Computershare Investor Services Übermittlungsbriefe mit Austausch-Anweisungen.
Positive
- Share consolidation helps maintain Nasdaq listing compliance
- Rounding up policy benefits shareholders with fractional shares of ½ or greater
Negative
- Potential shareholder dilution through 1:10 share consolidation
- Fractional shares less than ½ will be cancelled
Insights
BriaCell’s 1:10 share consolidation aims to maintain Nasdaq listing requirements, potentially indicating underlying financial challenges.
BriaCell Therapeutics is implementing a 1:10 share consolidation (reverse stock split) to ensure continued compliance with Nasdaq listing requirements. This restructuring, which takes effect on August 25, 2025, will convert every ten existing shares into one new share, with fractional shares being rounded accordingly.
This type of corporate action is typically undertaken when a company’s share price has fallen below Nasdaq’s minimum threshold (generally $1 per share) for a sustained period. While the consolidation mathematically increases the share price by reducing the number of outstanding shares, it does not change the company’s underlying value or market capitalization.
The timing suggests BriaCell may be approaching a deadline to regain compliance with Nasdaq’s requirements. Reverse splits are often viewed cautiously by the market as they can signal financial distress or an inability to naturally recover share value through operational improvements. For existing shareholders, while their ownership percentage technically remains unchanged, research shows that companies implementing reverse splits often experience continued downward pressure on their stock post-consolidation.
This move indicates BriaCell values its Nasdaq listing, which provides access to capital markets and institutional investors that might be critical for funding its clinical-stage biotechnology operations. However, the need for artificial price support through consolidation may reflect underlying challenges in attracting sufficient market interest at current valuations.
08/21/2025 – 12:00 PM
Philadelphia and Vancouver, British Columbia – August 21, 2025 – BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell”), a clinical-stage biotech firm focused on innovative immunotherapies, announced today a strategic move to consolidate its stock. A 1-for-10 reverse stock split has been approved by the board, designed to ensure continued compliance with Nasdaq listing requirements. The consolidation aims to bolster the share price, maintaining its position on the Nasdaq Capital Market.
The reverse split, pending approval from both the Toronto Stock Exchange (TSX) and Nasdaq, is slated to take effect on August 25, 2025. Trading of the post-consolidation shares is expected to commence that day on both exchanges under the symbols “BCT” on the TSX and “BCTX” on the Nasdaq, pending final confirmation.
To address fractional shares, BriaCell will implement a shareholder-friendly approach: fractions of one-half share or greater will be rounded up to a full share, while those less than half will be cancelled. Crucially, this rounding will occur at the participant level, not the individual beneficial holder level. Moreover, the exercise or conversion prices, along with the number of shares issuable under the company’s outstanding convertible securities, will undergo proportional adjustments to reflect the consolidation.
Shareholders of record will receive detailed instructions from Computershare Investor Services Inc., BriaCell’s transfer agent, outlining the process for exchanging their shares. Beneficial holders, who hold their shares through brokers or other intermediaries, need not take any action. Those with questions are encouraged to contact their respective intermediaries.
BriaCell’s move echoes a common strategy among companies navigating the rigorous demands of exchange compliance. While a reverse split does not inherently alter the underlying value of the company, it can provide a necessary boost to share price, maintaining access to capital markets and a broader investor base. The company’s filings on SEDAR+ and EDGAR offer additional details on the consolidation.
FAQ
What is the ratio of BriaCell’s (BCTX) share consolidation announced for August 2025?
BriaCell announced a 1-for-10 share consolidation, meaning shareholders will receive one new share for every ten existing shares.
When will BriaCell’s (BCTX) share consolidation become effective?
The share consolidation is expected to become effective on August 25, 2025, with post-consolidation shares beginning to trade on both TSX and Nasdaq at market open on the same day.
Why is BriaCell (BCTX) implementing a share consolidation in 2025?
BriaCell is implementing the share consolidation to ensure continued compliance with Nasdaq Capital Market listing requirements.
How will BriaCell (BCTX) handle fractional shares in the 2025 consolidation?
Fractional shares of ½ or greater will be rounded up to one whole share, while fractions less than ½ will be cancelled. Rounding occurs at the participant level, not the beneficial level.
What should BriaCell (BCTX) shareholders do to exchange their shares after the consolidation?
Registered shareholders will receive a letter of transmittal from Computershare with exchange instructions. Beneficial holders who own shares through intermediaries need not take any action.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/7790.html
